Group items tagged

The global immunotherapy drugs market will continue to grow, owing to increasing incidence of lifestyle-related and chronic disease globally, increasing product approvals, rising healthcare expenditures, and increasing access to better diagnostic & treatment facilities. High preference for immunotherapy over traditional chemotherapy and its use in combination with the same in first-line treatments coupled with high adoption of targeted therapies is expected to support the market growth during the forecast period 2019-2025. The immunotherapy drugs market, by type of drug, is segmented into monoclonal antibodies (mAbs), vaccine, non-specific immunotherapies, adaptive cell therapy, and others. Among these, monoclonal antibodies occupied a significant share in 2018 while the fastest growing type was adaptive cell therapy, which is expected to grow at a high CAGR during the forecast period 2019-2025. Increased preference for mAbs with fewer side-effects made this type the dominant market shareholder in 2018.

Advances in cancer treatments, such as immunotherapies and precision medicines, have been associated with a corresponding rise in the cost of new and innovative medicines.

Leukemia treatment is rapidly evolving with innovations like targeted therapy, immunotherapy, and stem cell transplants

the "Global Lung Cancer Drugs Market" will grow at a CAGR of 13.6% during the forecast period. The market has witnessed steady growth in the past few years with the introduction of novel products, which have augmented the acceptance of immunotherapy drugs in the market. The market is fueled by upsurge in the incidence of lung cancer cases across the globe - owing to increasing diagnosis rate and mainly due to increasing tobacco consumption, increase in the lung cancer treatment rates, increasing rate of effective drug approvals as first-line therapies, strategic deals to develop new products, increasing R&D spending, and rapid industrialization leading to increased pollution. The report provides complete details about the sub-segments of the lung cancer drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, and government initiatives towards the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market.